Trial Profile
Phase II, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections With Suspected or Confirmed Gram-Positive Bacterial Pathogens
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2017
Price :
$35
*
At a glance
- Drugs Dalbavancin (Primary)
- Indications Bacteraemia; Gram-positive infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Vicuron Pharmaceuticals
- 25 Apr 2017 Results of pooled analysis of clearance of bacteraemia data fro four phase III stuadies and a phase II study including this study presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
- 16 Jan 2017 New trial record